TEVET’s key industry partner, Agilent Technologies Inc. is set to expand solutions to design personalized medicine. Agilent will acquire the Belgium-based company Multiplicom by mid-January subject to local laws, regulations, and customary closing conditions.
Multiplicom develops and manufactures molecular-diagnostic solutions that enable personalized medicine. These solutions enable clinical labs to identify DNA variants linked to genetic disease, predisposition in patients, and identify congenital defects early in pregnancy. The acquisition will strengthen Agilent’s presence in the European market and add key products, offering better services to our customers in the genomics market.